Invesco Dynamic Pharmaceuticals ETF
PJP - ETF AI Analysis
Top Page
Invesco Dynamic Pharmaceuticals ETF (PJP)
PJP, the Invesco Dynamic Pharmaceuticals ETF, has a solid overall rating that reflects a portfolio led by strong, established drug makers with generally healthy financials and growth prospects. Key holdings like Merck and Johnson & Johnson support the fund’s quality through robust performance, positive earnings outlooks, and strategic pipelines, while weaker names such as Perrigo and Viatris, which face profitability and valuation challenges, slightly weigh on the rating. The main risk for investors is the fund’s concentration in the pharmaceutical sector, meaning it is heavily exposed to industry-specific issues like drug pricing pressures, patent risks, and regulatory changes.
PJP vs. SPDR S&P 500 ETF (SPY)
- AUM
- 609.17M
- Region
- North America
- Expense Ratio
- 0.58%
- Beta
- 0.53
- Issuer
- Invesco
- Inception Date
- Jun 23, 2005
- Dividend Yield
- 0.86%
- Asset Class
- Equity
- Index Tracked
- Dynamic Pharmaceutical Intellidex Index (AMEX)
PJP Summary
PJP is the Invesco Dynamic Pharmaceuticals ETF, which follows the Dynamic Pharmaceutical Intellidex Index. It focuses on U.S. drugmakers and health care companies involved in developing and selling medicines. The fund holds well-known names like Pfizer and Johnson & Johnson, along with other major pharmaceutical firms. Someone might invest in PJP to tap into the long-term growth potential of new treatments and the steady demand for health care, while spreading their money across many companies instead of picking just one. A key risk is that it is heavily concentrated in pharmaceutical stocks, so its value can rise or fall sharply with changes in the drug industry and health care regulations.
How much will it cost me?
PJP has an annual expense ratio of 0.58%, which means you’ll pay about $5.80 per year for every $1,000 invested. This cost is higher than the average ETF because it uses a more complex, actively managed strategy to select pharmaceutical stocks rather than simply tracking a broad market index.
What would affect this ETF?
PJP could benefit from ongoing demand for medicines, an aging U.S. population, and successful new drug launches by major holdings like AbbVie, Pfizer, Eli Lilly, and Johnson & Johnson, especially if health care policies remain supportive of innovation. On the negative side, tighter drug pricing rules, patent expirations, safety concerns, or slower economic growth in North America could hurt profits for these pharmaceutical companies and weigh on the ETF’s future returns.
PJP Top 10 Holdings
PJP is a pure play on big U.S. drugmakers, with heavy exposure to household pharma names. Amgen, Eli Lilly, and Gilead have been rising steadily, giving the fund much of its recent lift, while Pfizer and Johnson & Johnson add solid, if less exciting, support. On the flip side, Abbott has been lagging and acts as a bit of a speed bump, and Merck’s mixed near-term performance keeps it from fully pulling its weight. Overall, this is a concentrated bet on large-cap U.S. pharmaceuticals, with a few smaller players adding extra spice.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 6.16% | $37.42M | $1.34T | 41.12% | 72Outperform | |
| Gilead Sciences | 6.03% | $36.65M | $208.31B | 34.25% | 78Outperform | |
| AbbVie | 5.87% | $35.66M | $520.47B | 27.01% | 66Neutral | |
| Amgen | 5.59% | $33.93M | $252.64B | 38.59% | 77Outperform | |
| Pfizer | 5.45% | $33.12M | $164.33B | 12.02% | 74Outperform | |
| Johnson & Johnson | 5.43% | $32.98M | $682.52B | 46.35% | 78Outperform | |
| Merck & Company | 4.98% | $30.23M | $362.27B | 59.00% | 80Outperform | |
| Abbott Laboratories | 4.97% | $30.19M | $185.75B | -16.05% | 73Outperform | |
| Viatris | 3.80% | $23.07M | $23.70B | 90.83% | 60Neutral | |
| Amneal Pharmaceuticals | 3.65% | $22.19M | $7.56B | 85.59% | 58Neutral |
PJP Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PJP, the sentiment is Positive. The current price of 131.04 is above the 20-day moving average (MA) of 128.14, above the 50-day MA of 125.82, and above the 200-day MA of 115.29, indicating a bullish trend. The MACD of 1.54 indicates Negative momentum. The RSI at 59.39 is Neutral, neither overbought nor oversold. The STOCH value of 79.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PJP.
PJP Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $131.04 | $137.00(4.55% Upside) | $609.17M | 0.58% | 70Neutral | |
| $66.83 | $111.69(67.13% Upside) | $528.86M | 0.35% | 58Neutral | |
| $97.88 | $127.77(30.53% Upside) | $436.74M | 0.59% | 71Outperform | |
| $39.98 | $50.79(27.03% Upside) | $344.66M | 0.51% | 67Neutral | |
| $57.32 | $78.62(37.17% Upside) | $284.20M | 0.60% | 60Neutral | |
| $145.43 | $171.66(18.04% Upside) | $244.82M | 0.35% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PJP | Invesco Dynamic Pharmaceuticals ETF | 131.04 | 29.07 | 28.51% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 66.83 | 15.68 | 30.67% | |
| PBE | Invesco Dynamic Biotechnology & Genome ETF | 97.88 | 21.54 | 28.21% | |
| PINK | Simplify Health Care ETF | 39.98 | 3.96 | 11.00% | |
| PTH | Invesco DWA Healthcare Momentum ETF | 57.31 | 8.61 | 17.68% | |
| XHS | SPDR S&P Health Care Services ETF | 145.43 | 44.02 | 43.41% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
